Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews - PubMed (original) (raw)

Review

Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews

Aidan G Cashin et al. Cochrane Database Syst Rev. 2023.

Abstract

Background: Pharmacological interventions are the most used treatment for low back pain (LBP). Use of evidence from systematic reviews of the effects of pharmacological interventions for LBP published in the Cochrane Library, is limited by lack of a comprehensive overview.

Objectives: To summarise the evidence from Cochrane Reviews of the efficacy, effectiveness, and safety of systemic pharmacological interventions for adults with non-specific LBP.

Methods: The Cochrane Database of Systematic Reviews was searched from inception to 3 June 2021, to identify reviews of randomised controlled trials (RCTs) that investigated systemic pharmacological interventions for adults with non-specific LBP. Two authors independently assessed eligibility, extracted data, and assessed the quality of the reviews and certainty of the evidence using the AMSTAR 2 and GRADE tools. The review focused on placebo comparisons and the main outcomes were pain intensity, function, and safety.

Main results: Seven Cochrane Reviews that included 103 studies (22,238 participants) were included. There is high confidence in the findings of five reviews, moderate confidence in one, and low confidence in the findings of another. The reviews reported data on six medicines or medicine classes: paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, benzodiazepines, opioids, and antidepressants. Three reviews included participants with acute or sub-acute LBP and five reviews included participants with chronic LBP. Acute LBP Paracetamol There was high-certainty evidence for no evidence of difference between paracetamol and placebo for reducing pain intensity (MD 0.49 on a 0 to 100 scale (higher scores indicate worse pain), 95% CI -1.99 to 2.97), reducing disability (MD 0.05 on a 0 to 24 scale (higher scores indicate worse disability), 95% CI -0.50 to 0.60), and increasing the risk of adverse events (RR 1.07, 95% CI 0.86 to 1.33). NSAIDs There was moderate-certainty evidence for a small between-group difference favouring NSAIDs compared to placebo at reducing pain intensity (MD -7.29 on a 0 to 100 scale (higher scores indicate worse pain), 95% CI -10.98 to -3.61), high-certainty evidence for a small between-group difference for reducing disability (MD -2.02 on a 0-24 scale (higher scores indicate worse disability), 95% CI -2.89 to -1.15), and very low-certainty evidence for no evidence of an increased risk of adverse events (RR 0.86, 95% CI 0. 63 to 1.18). Muscle relaxants and benzodiazepines There was moderate-certainty evidence for a small between-group difference favouring muscle relaxants compared to placebo for a higher chance of pain relief (RR 0.58, 95% CI 0.45 to 0.76), and higher chance of improving physical function (RR 0.55, 95% CI 0.40 to 0.77), and increased risk of adverse events (RR 1.50, 95% CI 1. 14 to 1.98). Opioids None of the included Cochrane Reviews aimed to identify evidence for acute LBP. Antidepressants No evidence was identified by the included reviews for acute LBP. Chronic LBP Paracetamol No evidence was identified by the included reviews for chronic LBP. NSAIDs There was low-certainty evidence for a small between-group difference favouring NSAIDs compared to placebo for reducing pain intensity (MD -6.97 on a 0 to 100 scale (higher scores indicate worse pain), 95% CI -10.74 to -3.19), reducing disability (MD -0.85 on a 0-24 scale (higher scores indicate worse disability), 95% CI -1.30 to -0.40), and no evidence of an increased risk of adverse events (RR 1.04, 95% CI -0.92 to 1.17), all at intermediate-term follow-up (> 3 months and ≤ 12 months postintervention). Muscle relaxants and benzodiazepines There was low-certainty evidence for a small between-group difference favouring benzodiazepines compared to placebo for a higher chance of pain relief (RR 0.71, 95% CI 0.54 to 0.93), and low-certainty evidence for no evidence of difference between muscle relaxants and placebo in the risk of adverse events (RR 1.02, 95% CI 0.67 to 1.57). Opioids There was high-certainty evidence for a small between-group difference favouring tapentadol compared to placebo at reducing pain intensity (MD -8.00 on a 0 to 100 scale (higher scores indicate worse pain), 95% CI -1.22 to -0.38), moderate-certainty evidence for a small between-group difference favouring strong opioids for reducing pain intensity (SMD -0.43, 95% CI -0.52 to -0.33), low-certainty evidence for a medium between-group difference favouring tramadol for reducing pain intensity (SMD -0.55, 95% CI -0.66 to -0.44) and very low-certainty evidence for a small between-group difference favouring buprenorphine for reducing pain intensity (SMD -0.41, 95% CI -0.57 to -0.26). There was moderate-certainty evidence for a small between-group difference favouring strong opioids compared to placebo for reducing disability (SMD -0.26, 95% CI -0.37 to -0.15), moderate-certainty evidence for a small between-group difference favouring tramadol for reducing disability (SMD -0.18, 95% CI -0.29 to -0.07), and low-certainty evidence for a small between-group difference favouring buprenorphine for reducing disability (SMD -0.14, 95% CI -0.53 to -0.25). There was low-certainty evidence for a small between-group difference for an increased risk of adverse events for opioids (all types) compared to placebo; nausea (RD 0.10, 95% CI 0.07 to 0.14), headaches (RD 0.03, 95% CI 0.01 to 0.05), constipation (RD 0.07, 95% CI 0.04 to 0.11), and dizziness (RD 0.08, 95% CI 0.05 to 0.11). Antidepressants There was low-certainty evidence for no evidence of difference for antidepressants (all types) compared to placebo for reducing pain intensity (SMD -0.04, 95% CI -0.25 to 0.17) and reducing disability (SMD -0.06, 95% CI -0.40 to 0.29).

Authors' conclusions: We found no high- or moderate-certainty evidence that any investigated pharmacological intervention provided a large or medium effect on pain intensity for acute or chronic LBP compared to placebo. For acute LBP, we found moderate-certainty evidence that NSAIDs and muscle relaxants may provide a small effect on pain, and high-certainty evidence for no evidence of difference between paracetamol and placebo. For safety, we found very low- and high-certainty evidence for no evidence of difference with NSAIDs and paracetamol compared to placebo for the risk of adverse events, and moderate-certainty evidence that muscle relaxants may increase the risk of adverse events. For chronic LBP, we found low-certainty evidence that NSAIDs and very low- to high-certainty evidence that opioids may provide a small effect on pain. For safety, we found low-certainty evidence for no evidence of difference between NSAIDs and placebo for the risk of adverse events, and low-certainty evidence that opioids may increase the risk of adverse events.

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PubMed Disclaimer

Conflict of interest statement

MKB has received support from his institution (UNSW) for conference travel that is unrelated to the present work, from the Chiropractor’s Association of Australia to speak about pain rehabilitation and from the Memorial University of Newfoundland to speak about engagement with research evidence, including evidence about medicines. MKB’s salary was provided by scholarships. MKB is first author on the Cochrane Review ‘Paracetamol, NSAIDs or opioid analgesics for chronic low back pain: a network meta‐analysis’ and was not involved in any decisions about this review in the overview.

CGM has received competitive grants from government agencies and industry to support his research. As an invited speaker at conferences, he has had his expenses covered and also received small gifts such as a box of chocolates or a bottle of wine. He has received honoraria for marking theses, reviewing grants, and preparing talks. CGM is on the Editorial Board of the Cochrane Back and Neck Review Group. Mitigation of conflict of interest: CGM was not involved in editorial decisions on this review.

ADF: Google LLC, D/B/A YouTube (Independent Contractor ‐ Other). The institutions where ADF works have received various grants from external organisations, including government and public institutions in Ontario, Canada, and the UK.

MWvT is on the Editorial Board of the Cochrane Back and Neck Review Group. MWvT was Co‐ordinating Editor until September 2017. MWvT was not involved in editorial decisions on this review. MWvT has no additional competing interest; all research funding comes from non‐profit, governmental funding agencies, and all funding (including travel and stay expenses) were paid to the VU University.

HL has consulted for Cancer Council Australia and has received funding from the Australian Health and Medical Research Council (grant no. APP1126767), Center for Effective Global Action (CEGA), and Berkeley Initiative for Transparency in the Social Sciences (BITSS).

BMW has received payment for lectures on the non‐pharmacological management of chronic low back pain. He has received honoraria for marking theses related to low back pain.

AGC, NEO, RNRR, EO and JHM have no known declarations.

This research project did not receive any specific grant from funding agencies in the public, commercial, or not‐for‐profit sectors.

Figures

1

1

Flow diagram

Update of

Similar articles

Cited by

References

References to included reviews

Chaparro 2013
    1. Chaparro LE, Furlan AD, Deshpande A, Mailis‐Gagnon A, Atlas S, Turk DC. Opioids compared to placebo or other treatments for chronic low‐back pain. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD004959. [DOI: 10.1002/14651858.CD004959.pub4] - DOI - PMC - PubMed
Enthoven 2016
    1. Enthoven WT, Roelofs PD, Deyo RA, Van Tulder MW, Koes BW. Non‐steroidal anti‐inflammatory drugs for chronic low back pain. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No: CD012087. [DOI: 10.1002/14651858.CD012087] - DOI - PMC - PubMed
Santos 2015
    1. Santos J, Alarcão J, Fareleira F, Vaz Carneiro A, Costa J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No: CD009923. [DOI: 10.1002/14651858.CD009923.pub2] - DOI - PMC - PubMed
Saragiotto 2016
    1. Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane Database of Systematic Reviews 2016, Issue 6. Art. No: CD012230. [DOI: 10.1002/14651858.CD012230] - DOI - PMC - PubMed
Urquhart 2008
    1. Urquhart DM, Hoving JL, Assendelft WJ, Roland M, Van Tulder MW. Antidepressants for non‐specific low back pain. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD001703. [DOI: 10.1002/14651858.CD001703.pub3] - DOI - PMC - PubMed
Van der Gaag 2020
    1. Van der Gaag WH, Roelofs PD, Enthoven WT, Van Tulder MW, Koes BW. Non‐steroidal anti‐inflammatory drugs for acute low back pain. Cochrane Database of Systematic Reviews 2020, Issue 4. Art. No: CD013581. [DOI: 10.1002/14651858.CD013581] - DOI - PMC - PubMed
Van Tulder 2003
    1. Van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non‐specific low‐back pain. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No: CD004252. [DOI: 10.1002/14651858.CD004252] - DOI - PMC - PubMed

References to excluded reviews

Bagg 2018
    1. Bagg MK, McLachlan AJ, Maher CG, Kamper SJ, Williams CM, Henschke N, et al. Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta‐analysis. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No: CD013045. [DOI: 10.1002/14651858.CD013045] - DOI
Bezerra 2014
    1. Bezerra DM, El Dib R, Vidal EI, De Barros GA, Chou R, Fukushima F. Anticonvulsants for chronic low‐back pain. Cochrane Database of Systematic Reviews 2014, Issue 6 . Art. No: CD011171. [DOI: 10.1002/14651858.CD011171] - DOI
Chou 2016a
    1. Chou R, Pinto RZ, Fu R, Lowe RA, Henschke N, Dana T. Systemic corticosteroids for radicular and non‐radicular low back pain. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No: CD012450. [DOI: 10.1002/14651858.CD012450] - DOI - PMC - PubMed
Dagenais 2007
    1. Dagenais S, Yelland MJ, Del Mar C, Schoene ML. Prolotherapy injections for chronic low‐back pain. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No: CD004059. [DOI: 10.1002/14651858.CD004059.pub3] - DOI - PMC - PubMed
Derry 2014a
    1. Derry CJ, Derry S, Moore RA. Caffeine as an analgesic adjuvant for acute pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No: CD009281. [DOI: 10.1002/14651858.CD009281.pub3] - DOI - PMC - PubMed
Derry 2014b
    1. Derry S, Matthews PR, Wiffen PJ, Moore RA. Salicylate‐containing rubefacients for acute and chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No: CD007403. [DOI: 10.1002/14651858.CD007403.pub3] - DOI - PMC - PubMed
Derry 2015
    1. Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 6. Art. No: CD007402. [DOI: 10.1002/14651858.CD007402.pub3] - DOI - PMC - PubMed
Derry 2016
    1. Derry S, Conaghan P, Da Silva JA, Wiffen PJ, Moore RA. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews 2016, Issue 4. Art. No: CD007400. [DOI: 10.1002/14651858.CD007400.pub3] - DOI - PMC - PubMed
Furlan 2014
    1. Furlan AD, Irvin E, Kim J, Van Eerd D, Carnide N, Munhall C, et al. Impact of long‐term opioid use for chronic non‐cancer pain on misuse, abuse or addiction, overdose, falls and fractures. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No: CD011062. [DOI: 10.1002/14651858.CD011062] - DOI
Haroutounian 2012
    1. Haroutounian S, McNicol ED, Lipman AG. Methadone for chronic non‐cancer pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No: CD008025. [DOI: 10.1002/14651858.CD008025.pub2] - DOI - PMC - PubMed
Noble 2010
    1. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long‐term opioid management for chronic noncancer pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD006605. [DOI: 10.1002/14651858.CD006605.pub2] - DOI - PMC - PubMed
Oltean 2014
    1. Oltean H, Robbins C, Van Tulder MW, Berman BM, Bombardier C, Gagnier JJ. Herbal medicine for low‐back pain. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No: CD004504. [DOI: 10.1002/14651858.CD004504.pub4] - DOI - PMC - PubMed
Quigley 2013
    1. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD003447. [DOI: 10.1002/14651858.CD003447.pub2] - DOI - PMC - PubMed
Roelofs 2008
    1. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, Van Tulder MW. Non‐steroidal anti‐inflammatory drugs for low back pain. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No: CD000396. [DOI: 10.1002/14651858.CD000396.pub3] - DOI - PMC - PubMed
Samuel 2012
    1. Samuel S, David KS, Gray RJ, Tharyan P. Fusion versus conservative management for low‐grade isthmic spondylolisthesis. Cochrane Database of Systematic Reviews 2012, Issue 10. Art. No: CD010150. [DOI: 10.1002/14651858.CD010150] - DOI
Seidel 2013
    1. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No: CD004844. [DOI: 10.1002/14651858.CD004844.pub3] - DOI - PMC - PubMed
Soares 2014
    1. Soares A, Andriolo RB, Atallah ÁN, da Silva EM. Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No: CD007533. [DOI: 10.1002/14651858.CD007533.pub2] - DOI - PMC - PubMed
Staal 2008
    1. Staal JB, Bie R, Vet HC, Hildebrandt J, Nelemans P. Injection therapy for subacute and chronic low‐back pain. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No: CD001824. [DOI: 10.1002/14651858.CD001824.pub3] - DOI - PMC - PubMed
Waseem 2011
    1. Waseem Z, Boulias C, Gordon A, Ismail F, Sheean G, Furlan AD. Botulinum toxin injections for low‐back pain and sciatica. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No: CD008257. [DOI: 10.1002/14651858.CD008257.pub2] - DOI - PubMed
Wiffen 2010
    1. Wiffen PJ, Collins S, McQuay HJ, Carroll D, Jadad A, Moore RA. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD001133. [DOI: 10.1002/14651858.CD001133.pub3] - DOI - PMC - PubMed
Wiffen 2011
    1. Wiffen PJ, McQuay HJ, Edwards J, Moore RA. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No: CD005452. [DOI: 10.1002/14651858.CD005452.pub2] - DOI - PMC - PubMed
Zaina 2016
    1. Zaina F, Tomkins‐Lane C, Carragee E, Negrini S. Surgical versus non‐surgical treatment for lumbar spinal stenosis. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No: CD010264. [DOI: 10.1002/14651858.CD010264] - DOI - PMC - PubMed

Additional references

Abajobir 2017
    1. Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study. Lancet 2017;390(10100):1211-59. - PMC - PubMed
Abdel Shaheed 2021
    1. Abdel Shaheed C, Ferreira GE, Dmitritchenko A, McLachlan AJ, Day RO, Saragiotto B, et al. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. Medical Journal of Australia 2021;214(7):324-31. - PubMed
Anderson 2022
    1. Anderson DB, Shaheed AC. Medications for treating low back pain in adults. Evidence for the use of paracetamol, opioids, nonsteroidal anti-inflammatories, muscle relaxants, antibiotics, and antidepressants:an overview for musculoskeletal clinicians. Journal of Orthopaedic and Sports Physical Therapy 2022;52(7):425-31. - PubMed
Bachhuber 2016
    1. Bachhuber M, Hennessy S, Cunningham C, Starrels J. Increasing benzodiazepine prescriptions and overdose mortality in the United States, 1996-2013. American Journal of Public Health 2016;106(4):686-8. - PMC - PubMed
Bagg 2018a
    1. Bagg MK, Salanti G, McAuley JH. Research note: comparing interventions with network meta-analysis. Journal of Physiotherapy 2018;64:128-32. - PubMed
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64:401-6. - PubMed
Barden 2006
    1. Barden J, Derry S, McQuay HJ, Moore AR. Bias from industry trial funding? A framework, a suggested approach, and a negative result. Pain 2006;121(3):207-18. - PubMed
Bourgeois 2010
    1. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Annals of Internal Medicine 2010;153(3):158-66. - PMC - PubMed
Brune 2015
    1. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of Pain Research 2015;8:105-18. - PMC - PubMed
Carey 2009
    1. Carey TS, Freburger JK, Holmes GM, Castel L, Darter J, Agans R, et al. A long way to go: practice patterns and evidence in chronic low back pain care. Spine 2009;7(34):718-24. - PMC - PubMed
Cashin 2020
    1. Cashin AG, Wand BM, O'Connell NE, Lee H, Bagg MK, O'Hagan E, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No: CD013815. [DOI: 10.1002/14651858.CD013815] - DOI - PMC - PubMed
Cashin 2021
    1. Cashin AG, Folly T, Bagg MK, Wewege MA, Jones MD, Ferraro MC, et al. Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis. BMJ 2021;374:n1446. - PMC - PubMed
Chiarotto 2015
    1. Chiarotto A, Deyo RA, Terwee CB, Boers M, Buchbinder R, Corbin TP, et al. Core outcome domains for clinical trials in non-specific low back pain. European Spine Journal 2015;24(6):1127-42. - PubMed
Chopra 2003
    1. Chopra SS. Industry funding of clinical trials: benefit or bias? JAMA 2003;290(1):113-4. - PubMed
Chou 2010
    1. Chou R. Pharmacological management of low back pain. Drugs 2010;70(4):387-402. - PubMed
Chou 2016
    1. Chou R, Pinto R, Fu R, Lowe R, Henschke N, Duna T. Systemic corticosteroids for radicular and non-radicular low back pain. Cochrane Database of Systematic Reviews 2016, Issue 12. Art. No: CD012450. [DOI: 10.1002/14651858.CD012450] - DOI - PMC - PubMed
Chou 2017
    1. Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Annals of Internal Medicine 2017;166(7):480-92. - PubMed
Chou 2018a
    1. Chou L, Ranger TA, Peiris W, Cicuttini FM, Urquhart DM, Sullivan K, et al. Patients' perceived needs of health care providers for low back pain management: a systematic scoping review. Spine 2018;18(4):691-711. - PubMed
Chou 2018b
    1. Chou L, Ranger TA, Peiris W, Cicuttini FM, Urquhart DM, Sullivan K, et al. Patients' perceived needs for medical services for non-specific low back pain: A systematic scoping review. PLOS One 2018;13(11):1-29. - PMC - PubMed
Cleeland 1989
    1. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors(s). Issues in Pain Measurement. Advances in Pain Research and Management. Vol. 12. New York: Raven Press, 1989:391-403.
Cohen 2001
    1. Cohen SP, Abdi S. New developments in the use of tricyclic antidepressants for the management of pain. Current Opinion in Anaesthesiology 2001;14(5):505-11. - PubMed
Covidence [Computer program]
    1. Covidence. Melbourne, Australia: Veritas Health Innovation, Accessed prior to 24 November 2020. Available at covidence.org.
Derry 2019
    1. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2019, Issue 1. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub3] - DOI - PMC - PubMed
Deyo 2015
    1. Deyo RA, Von Korff M, Duhrkoop D. Opioids for low back pain. BMJ 2015;350:g6380. - PMC - PubMed
Dieleman 2016
    1. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, et al. US spending on personal health care and public health, 1996-2013. Journal of the American Medical Association 2016;316(24):2627-46. - PMC - PubMed
Dieleman 2020
    1. Dieleman JL, Cao J, Chapin A, Chen C, Li Z, Liu A, et al. US health care spending by payer and health condition, 1996-2016. Journal of the American Medical Association 2020;323(9):863-84. - PMC - PubMed
Dosenovic 2018
    1. Dosenovic S, Jelicic Kadic A, Vucic K, Markovina N, Pieper D, Puljak L. Comparison of methodological quality rating of systematic reviews on neuropathic pain using AMSTAR and R-AMSTAR. BMC Medical Research Methodology 2018;18:37. - PMC - PubMed
Dworkin 2005
    1. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113(1):9-19. - PubMed
EndNote 2017 [Computer program]
    1. EndNote. Clarivate Analytics, 2017.
Fairbank 1980
    1. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability questionnaire. Physiotherapy 1980;66(8):271-3. - PubMed
Ferraro 2021
    1. Ferraro MC, Bagg MK, Wewege MA, Cashin AG, Leake HB, Rizzo RRN, et al. Efficacy, acceptability, and safety of antidepressants for low back pain: a systematic review and meta-analysis. Systematic Review 2021;10:62. - PMC - PubMed
Ferreira 2013
    1. Ferreira ML, Herbert RD, Ferreira PH, Latimer J, Ostelo RW, Grotle M, et al. The smallest worthwhile effect of nonsteroidal anti-inflammatory drugs and physiotherapy for chronic low back pain: a benefit-harm trade-off study. Journal of Clinical Epidemiology 2013;66(12):1397-404. - PubMed
Foster 2018
    1. Foster NE, Anema JR, Cherkin D, Chou R, Cohen SP, Gross DP, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet 2018;391(10137):2368-83. - PubMed
Furlan 2009
    1. Furlan AD, Pennick V, Bombardier C, Van Tulder M, Editorial Board, Cochrane Back Review Group. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 2009;34(18):1929-41. - PubMed
Furlan 2015
    1. Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, et al, for the Editorial Board of the Cochrane Back, Neck Group. 2015 Updated Method Guideline for Systematic Reviews in the Cochrane Back and Neck Group. Spine 2015;40(21):1660-73. - PubMed
Goldkuhle 2018
    1. Goldkuhle M, Narayan VM, Weigl A, Dahm P, Skoetz N. A systematic assessment of Cochrane reviews and systematic reviews published in high-impact medical journals related to cancer. BMJ Open 2018;8:e020869. - PMC - PubMed
Gore 2012
    1. Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Practice 2012;12(7):550-60. - PubMed
Gouveia 2017
    1. Gouveia N, Rodrigues A, Ramiro S, Eusébio M, Machado PM, Canhão H, et al. The use of analgesic and other pain-relief drugs to manage chronic low back pain: results from a national survey. Pain Practice 2017;17(3):353-65. - PubMed
Guy 1976
    1. Guy W. ECDEU assessment manual for psychopharmacology . US Government Printing Office, 1976.
Hancock 2007
    1. Hancock MJ, Maher CG, Latimer J, Spindler MF, McAuley JH, Laslett M, et al. Systematic review of tests to identify the disc, SIJ or facet joint as the source of low back pain. European Spine Journal 2007;16(10):1539-50. - PMC - PubMed
Harmer 2017
    1. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry 2017;4(5):409-18. - PMC - PubMed
Hart 2015
    1. Hart OR, Uden RM, McMullen JE, Ritchie MS, Williams TD, Smith BH. A study of National Health Service management of chronic osteoarthritis and low back pain. Primary Health Care Research and Development 2015;16(2):157-66. - PMC - PubMed
Hennessy 2020
    1. Hennessy EA, Johnson BT. Examining overlap of included studies in meta‐reviews: guidance for using the corrected covered area index. Research Synthesis Methods 2020;11:134-45. - PMC - PubMed
Henschke 2008
    1. Henschke N, Maher CG, Refshauge KM, Herbert RD, Cumming RG, Bleasel J, et al. Prognosis in patients with recent onset low back pain in Australian primary care: inception cohort study. BMJ 2008;337:a171. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. - PMC - PubMed
Higgins 2019
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley & Sons Ltd, 2019.
Higgins 2022
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3. Cochrane, 2022. Available from training.cochrane.org/handbook. - PMC - PubMed
Hong 2013
    1. Hong J, Reed C, Novick D, Happich M. Costs associated with treatment of chronic low back pain. Spine 2013;38(1):75-82. - PubMed
Hood 2014
    1. Hood S, Norman A, Hince D, Melichar J, Hulse G. Benzodiazepine dependence and its treatment with low dose flumazenil. British Journal of Clinical Pharmacology 2014;77(2):285-94. - PMC - PubMed
Hoy 2012
    1. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. A systematic review of the global prevalence of low back pain. Arthritis and Rheumatism 2012;64(6):2028-37. - PubMed
Hunt 2018
    1. Hunt H, Pollock A, Campbell P, Estcourt L, Brunton G. An introduction to overviews of reviews: planning a relevant research question and objective for an overview. Systematic Reviews 2018;7(1):39. - PMC - PubMed
Ioannidis 2009
    1. Ioannidis JP, Evans SJ, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781-8. - PubMed
Ivanova 2011
    1. Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine 2011;7(11):622-32. - PubMed
Jóźwiak‐Bebenista 2014
    1. Jóźwiak-Bebenista M, Nowak JZ. Paracetamol: mechanism of action, applications and safety concern. Acta Poloniae Pharmaceutica 2014;71(1):11-23. - PubMed
Kalso 2004
    1. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80. - PubMed
Koes 2006
    1. Koes BW, Van Tulder MW, Thomas S. Diagnosis and treatment of low back pain. BMJ 2006;332(7555):1430-4. - PMC - PubMed
Koes 2007
    1. Koes BW, Van Tulder MW, Peul WC. Diagnosis and treatment of sciatica. BMJ 2007;334(7607):1313-7. - PMC - PubMed
Koes 2018
    1. Koes BW, Backes D, Bindels PJ. Pharmacotherapy for chronic non-specific low back pain: current and future options. Expert Opinion on Pharmacotherapy 2018;19(6):537-45. - PubMed
Kyu 2018
    1. Kyu HH, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392(10159):1859-922. - PMC - PubMed
Lim 2019
    1. Lim YZ, Chou L, Au RT, Seneviwickrama KM, Cicuttini FM, Briggs AM, et al. People with low back pain want clear, consistent and personalised information on prognosis, treatment options and self-management strategies: a systematic review. Journal of Physiotherapy 2019;65(3):124-35. - PubMed
Lundh 2017
    1. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: MR000033. [DOI: 10.1002/14651858.MR000033.pub3] - DOI - PMC - PubMed
Maher 2017
    1. Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet 2017;389(10070):736-47. - PubMed
Maizels 2005
    1. Maizels M, Mccarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. American Family Physician 2005;71(3):483-90. - PubMed
McCrae 2018
    1. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol: a review. British Journal of Clinical Pharmacology 2018;84(10):2218-30. - PMC - PubMed
Meader 2014
    1. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. BMC Systematic Reviews 2014;3:82. - PMC - PubMed
Menezes Costa 2012
    1. Menezes Costa LC, Maher C, Hancock M, McAuley J, Herbert R, Costa L. The prognosis of acute and persistent low back pain: a meta-analysis. Canadian Medical Association Journal 2012;184(11):613-24. - PMC - PubMed
Michaleff 2012
    1. Michaleff ZA, Harrison C, Britt H, Lin CW, Maher CG. Ten-year survey reveals differences in GP management of neck and back pain. European Spine Journal 2012;21(7):1283-9. - PMC - PubMed
Micó 2006
    1. Micó JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends in Pharmacological Sciences 2006;27(7):348-54. - PubMed
Mills 2012
    1. Mills EJ, Ioannidis JP, Thorlund K, Schunemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308:1246-53. - PubMed
O'Neill 2014
    1. O'Neill J, Tabish H, Welch V, Petticrew M, Pottie K, Clarke M, et al. Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health. Journal of Clinical Epidemiology 2014;67:56-64. - PubMed
Oliveira 2018
    1. Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin CC, Chenot JF, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. European Spine Journal 2018;27(11):2791-803. - PubMed
Page 2016
    1. Page MJ, Shamseer L, Altman DG, Tetzlaff J, Sampson M, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS medicine 2016;13(5):e1002028. - PMC - PubMed
Piccoliori 2013
    1. Piccoliori G, Engl A, Gatterer D, Sessa E, in der Schmitten J, Abholz HH. Management of low back pain in general practice - is it of acceptable quality: an observational study among 25 general practices in South Tyrol (Italy). BMC Family Practice 2013;14(1):148. - PMC - PubMed
Pieper 2014
    1. Pieper D, Antoine S, Mathes T, Neugebauer E, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. Journal of Clinical Epidemiology 2014;67(4):368-75. - PubMed
Pollock 2017
    1. Pollock M, Fernandes RM, Hartling L. Evaluation of AMSTAR to assess the methodological quality of systematic reviews in overviews of reviews of healthcare interventions. BMC Medical Research Methodology 2017;17:1-13. - PMC - PubMed
Qaseem 2017
    1. Qaseem A, Wilt T, McLean R, Forciea M. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine 2017;166(7):514-30. - PubMed
Qureshi 2021
    1. Qureshi R, Mayo-Wilson E, Li T. Summaries of harms in systematic reviews are unreliable Paper 1: an introduction to research on harms. Journal of Clinical Epidemiology 2021;143:186-96. - PMC - PubMed
Rivat 2016
    1. Rivat C, Ballantyne J. The dark side of opioids in pain management: basic science explains clinical observation. Pain Reports 2016;1(2):e570. - PMC - PubMed
Roberts 2016
    1. Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Annals of Rheumatic Diseases 2016;75(3):552-9. - PMC - PubMed
Roland 1983
    1. Roland M, Morris R. A study of the natural history of back pain, part 1: development of a reliable and sensitive measure of disability in low-back pain. Spine 1983;8:141-144. - PubMed
Salanti 2012
    1. Salanti G. Indirect and mixed-treatment comparison, network, or multiple- treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods 2012;3:80-97. - PubMed
Schofield 2008
    1. Schofield DJ, Shrestha RN, Passey ME, Earnest A, Fletcher SL. Chronic disease and labour force participation among older Australians. Medical Journal of Australia 2008;189(8):447-50. - PubMed
Schofield 2012
    1. Schofield DJ, Callander EJ, Shrestha RN, Percival R, Kelly SJ, Passey ME. Labor force participation and the influence of having back problems on income poverty in Australia. Spine 2012;37(13):1156-63. - PubMed
Schulz 2010
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. - PMC - PubMed
See 2008
    1. See S, Ginzburg R. Choosing a skeletal muscle relaxant. American Family Physician 2008;78(3):365-70. - PubMed
Shea 2017
    1. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. - PMC - PubMed
TOP 2015
    1. Toward Optimized Practice (TOP) Low Back Pain Working Group. Evidence-informed Primary Care Management of Low Back Pain: Clinical Practice Guideline. Edmonton (AB): Toward Optimized Practice, 2015.
Trevor 2018
    1. Trevor A, Katzung B, Masters S. Katzung and Trevor's pharmacology: examination and board review. 12th edition. New York (NY): McGraw-Hill Education, 2018.
Van der Laan 2008
    1. Van der Laan S, Meijer O. Pharmacology of glucocorticoids: beyond receptors. European Journal of Pharmacology 2008;585(2-3):483-91. - PubMed
Van der Linden 2009
    1. Van der Linden MW, Van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases 2009;68:668-673. - PubMed
Van Tulder 1997
    1. Van Tulder MW, Assendelft WJ, Koes BW, Bouter LM, Editorial Board of the Cochrane Collaboration Back Review Group. Method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group for Spinal Disorders. Spine 1997;22(20):2323-30. - PubMed
Van Tulder 2003a
    1. Van Tulder M, Furlan A, Bombardier C, Bouter L, Editorial Board of the Cochrane Collaboration Back Review Group. Updated method guidelines for systematic reviews in the Cochrane Collaboration Back Review Group. Spine 2003;28(12):1290-9. - PubMed
Waljee 2017
    1. Waljee A, Rogers M, Lin P, Singal A, Stein J, Marks R et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ 2017;357:j1415. - PMC - PubMed
Ware 2000
    1. Ware JE. SF-36 health survey update. Spine 2000;25(24):3130-9. - PubMed
Wewege 2020
    1. Wewege MA, Bagg MK, Jones MD, McAuley JK, The ANiMALIA investigators. Analgesic medicines for adults with low back pain: protocol for a systematic review and network meta-analysis. Systematic Reviews 2020;9:255. - PMC - PubMed
Witenko 2014
    1. Witenko C, Moorman-Li R, Motycka C, Duane K, Hincapie-Castillo J, Leonard P, et al. Considerations for the appropriate use of skeletal muscle relaxants for the management of acute low back pain. Pharmacy and Therapeautics 2014;39(6):427-35. - PMC - PubMed
Zorzela 2014
    1. Zorzela L, Golder S, Liu Y, Pilkington K, Hartling L, Joffe A, et al. Quality of reporting in systematic reviews of adverse events: systematic review. BMJ 2014;348:f7668. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources